耐碳青霉烯类鲍曼不动杆菌感染的治疗进展  

Progress in treatment of carbapenem resistant Acinetobacter baumannii infection

作　　者：李国庆 陶倩 李国辉 Li Guoqing;Tao Qian;and Li Guohui(Pharmacy Department,Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University,Ji'nan 250000)

机构地区：[1]山东第一医科大学附属济南妇幼保健院药剂科,济南250000

出　　处：《中国抗生素杂志》2024年第8期841-850,共10页Chinese Journal of Antibiotics

摘　　要：鲍曼不动杆菌是一种革兰阴性杆菌,可引起多种严重感染。碳青霉烯类药物曾被人们认为是治疗鲍曼不动杆菌感染的首选药物之一。然而,随着耐碳青霉烯类鲍曼不动杆菌的出现,临床上可供选择的敏感药物越来越少,如何治疗耐碳青霉烯类鲍曼不动杆菌的感染已成为一个亟需解决的难题。本文从治疗现状、新型化合物以及新型治疗方法等3个方面,对治疗耐碳青霉烯类鲍曼不动杆菌的最新研究成果进行总结,旨在为耐碳青霉烯类鲍曼不动杆菌感染的临床治疗和新型药物开发提供参考。Acinetobacter baumannii is a Gram-negative bacillus that causes multiple infections that can become severe.Carbapenems were once considered one of the drugs of choice for the treatment of Acinetobacter baumannii infection.However,with the emergence of carbapenem-resistant Acinetobacter baumannii,there are fewer and fewer sensitive drugs available in the clinic,and how to treat the infection of carbapenem-resistant Acinetobacter baumannii has become an urgent problem to be solved.This article summarized the latest research results in the treatment of carbapenem-resistant Acinetobacter baumannii from three aspects:Current treatment status,new compounds and new treatment methods,aiming to provide references for the clinical treatment and development of new drugs for carbapenem-resistant Acinetobacter baumannii.

关 键 词：鲍曼不动杆菌 耐碳青霉烯 药物 治疗方法 进展 

分 类 号：R978.1[医药卫生—药品]